Capitalizing on the Progress in Hematology and Oncology, New Leadership Positions Arise
Jamie Flerlage and Jeffrey Andolina have taken on key roles to lead and advance the hospital’s efforts in treating and researching blood disorders and cancers in children.
Jamie Flerlage, M.D., M.P.H. will serve as the division chief and academic director of the Division of Pediatric Hematology/Oncology. Known for her leadership in pediatric oncology, Flerlage brings expertise in pediatric hematology/oncology, with a focus on improving patient outcomes and advancing new therapies. Flerlage is nationally and internationally recognized for her expertise in pediatric Hodgkin’s lymphoma. She previously worked at St. Jude Children’s Research Hospital, where she trained in pediatric hematology/oncology and became a faculty member. In her new roles, Flerlage will lead national and international groups focused on research and clinical trials for Hodgkin’s lymphoma. She will also work to expand external and collaborative clinical research opportunities in Rochester and beyond. Flerlage's start date is October 1.
Jeffrey Andolina, M.D. has been appointed as the clinical director of Pediatric Hematology and Oncology and associate chair for Pediatric Program Development for Golisano Children's Hospital. Andolina is a well-respected clinician and leader with expertise in the treatment and care of children with leukemia and lymphoma, as well as other cancers and blood diseases. His research interests include improving bone-marrow transplantation outcomes for children and young adults and evaluating reduced-intensity conditioning regimens for pediatric patients with malignant and non-malignant diseases, especially sickle cell anemia.
Together, Flerlage and Andolina form a leadership team aimed at strengthening Golisano Children’s Hospital’s Pediatric Hematology/Oncology division, enhancing patient care, and fostering innovative research to improve the lives of children facing blood disorders and cancers. Jill Halterman, MD, MPH, interim chair of the Department of Pediatrics, looks forward to the continued progress in the clinical mission and developing advanced treatments under the leadership of Andolina and Flerlage. Jonathan W. Friedberg, MD, MMSc, director of Wilmot Cancer Institute, welcomes Flerlage to Rochester, stating that her presence will be a significant asset for clinical research efforts, particularly for childhood cancers.
The new leadership roles aim to advance Golisano Children's Hospital's growing reputation in the field of pediatric cancer, as the division was nationally ranked in 2023 by U.S. News & World Report. Both Flerlage and Andolina are expected to build on the Division's national reputation for providing the highest quality of care. In their roles, they will direct inpatient and outpatient clinical services for the division, lead clinical program development, and promote a unified approach to the medical care of pediatric hematology/oncology patients.
The new leadership team is poised to make a significant impact on the lives of children facing blood disorders and cancers, as they work to improve patient outcomes and advance the field of pediatric hematology/oncology.
- The advancement of new therapies in pediatric oncology, a focus of Jamie Flerlage, is rooted in science and health-and-wellness, aiming to improve patient outcomes.
- Jeffrey Andolina's research interests in improving bone-marrow transplantation outcomes and reduced-intensity conditioning regimens for pediatric patients align with the field of medical-conditions, specifically cancers and blood diseases.
- The financial aspect of the hospital's endeavors, particularly in the business realm, is expected to grow as Flerlage and Andolina strengthen the reputation of Golisano Children’s Hospital in the field of pediatric cancer, attracting more federal/private grants for clinical trials.
